BMX Primary Antibody

Item Information
Catalog #Size/ConcentrationPrice
Specification
AliasesETK; PSCTK2; PSCTK3; BMX
ProductOrderB
Clone#1C6
Entrez GenelD660
FormulationAscitic fluid containing 0.03% sodium azide.
HostMouse
IsotypeIgG1
ImmunogenPurified recombinant fragment of human BMX expressed in E. Coli.
MW78kDa
Shipping InformationThis product will ship in a box containing blue ice at a temperature of 4°C. Learn More
Species ReactivityHuman
Application
ELISA1/10000
WB (Western Blot)1/500 - 1/2000
Sequence
138-276
Catalog#: 30043
Inquire
Contact us to order
Images
Western Blot
Figure 1: Western blot analysis using BMX mAb against BMX(AA: 138-276)-hIgGFc transfected HEK293 cell lysate.
Figure 1: Western blot analysis using BMX mAb against BMX(AA: 138-276)-hIgGFc transfected HEK293 cell lysate.
Product Overview
Description

BMX (bone marrow X kinase) is a cytoplasmic tyrosine kinase identified by reverse transcription of mRNA isolated from human bone marrow and mapped to the chromosomal band Xp22.2. The full length protein is 675 amino acids with a tyrosine kinase domain, an amino terminal pleckstrin domain, as well as an SH3 and SH2 domain. Direct comparison of BMX's primary sequence with other kinases showed that this is highly related to the family of BTK/ITK/TEC. BMX kinase is expressed in fetal and adult tissues, with the highest expression in heart, testis, small intestine and colon. It is undetectable in spleen, brain, kidney, and pancreas. Further analysis of mRNA expression showed that BMX is expressed in hematopoietic tissues and neutrophilic granulocytes, and in patients with acute and myeloid leukemia. The levels of BMX mRNA were substantially lower in patients with acute and chronic lymphoid leukemias, thus suggesting that BMX may be important during myelopoiesis.CST:It is expressed in a variety of hematopoietic, epithelial and endothelial cells.

References (references)
References (references)1. Oncogene. 2004 Mar 11;23(10):1838-44.
2. Nat Cell Biol. 2005 Aug;7(8):797-807.
3. Blood. 2008 Feb 15;111(4):1781-8.